1. Home
  2. ALLR vs ADIL Comparison

ALLR vs ADIL Comparison

Compare ALLR & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

21.5M

Sector

Health Care

ML Signal

HOLD

Logo Adial Pharmaceuticals Inc

ADIL

Adial Pharmaceuticals Inc

HOLD

Current Price

$4.90

Market Cap

18.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLR
ADIL
Founded
2004
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.5M
18.5M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
ALLR
ADIL
Price
$1.22
$4.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$9.75
$37.50
AVG Volume (30 Days)
75.7K
63.4K
Earning Date
05-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$320,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$0.13
52 Week High
$1.88
$7.20

Technical Indicators

Market Signals
Indicator
ALLR
ADIL
Relative Strength Index (RSI) 39.68 58.97
Support Level $1.22 $1.63
Resistance Level $1.45 $6.41
Average True Range (ATR) 0.09 0.68
MACD -0.02 -0.05
Stochastic Oscillator 14.61 58.94

Price Performance

Historical Comparison
ALLR
ADIL

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

About ADIL Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.

Share on Social Networks: